Dextenza in the Post-op Management of Vitreoretinal Surgeries

Eligibility Criteria

• * Men and women \>18 years old
• * Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.
• * Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and/or implant of a drug delivery system
• * History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye
• * Structural lid abnormalities such as ectropion or entropion in surgical eye
• * Ongoing use of systemic narcotic pain relievers
• * Presence of any intraocular inflammation (cells and flare) in the study eye at screening/baseline
• * Pain score greater than "0" on the ocular pain assessment in the study eye at screening/baseline
• * Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes
• * Other ocular surgeries or procedures during the study period and/or 6 months prior
• * Intraoperative complications
• * Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled.
• * Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication.
• * Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery.
• * Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.
• * Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure
• * Are pregnant or nursing/lactating
• * Participation as a subject in any clinical study within the 30 days prior to randomization.
• * Surgeries using 20 gauge or 23 gauge instruments.